Philadelphia Financial Management of San Francisco LLC acquired a new stake in ASP Isotopes Inc. (NASDAQ:ASPI – Free Report) during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 1,343,007 shares of the company’s stock, valued at approximately $8,353,504. ASP Isotopes accounts for approximately 0.0% of Philadelphia Financial Management of San Francisco LLC’s holdings, making the stock its 19th biggest holding. Philadelphia Financial Management of San Francisco LLC owned about 0.88% of ASP Isotopes as of its most recent filing with the Securities and Exchange Commission.
A number of other hedge funds and other institutional investors have also made changes to their positions in ASPI. BlackRock Inc. bought a new stake in ASP Isotopes in the second quarter worth approximately $57,331,000. Encompass Capital Advisors LLC acquired a new position in shares of ASP Isotopes during the 1st quarter valued at $30,551,000. Alyeska Investment Group L.P. increased its stake in shares of ASP Isotopes by 73.4% during the 4th quarter. Alyeska Investment Group L.P. now owns 4,895,546 shares of the company’s stock worth $26,191,000 after purchasing an additional 2,072,851 shares during the last quarter. Vanguard Group Inc. boosted its holdings in shares of ASP Isotopes by 37.9% in the 3rd quarter. Vanguard Group Inc. now owns 4,516,763 shares of the company’s stock worth $43,451,000 after purchasing an additional 1,241,024 shares in the last quarter. Finally, Rovida Investment Management Ltd raised its holdings in ASP Isotopes by 28.1% in the fourth quarter. Rovida Investment Management Ltd now owns 4,100,000 shares of the company’s stock worth $21,894,000 after purchasing an additional 900,000 shares in the last quarter. Institutional investors own 16.80% of the company’s stock.
ASP Isotopes Stock Down 4.0%
Shares of ASPI stock traded down $0.16 during trading hours on Friday, hitting $3.88. 2,754,434 shares of the company’s stock traded hands, compared to its average volume of 4,827,331. The company has a quick ratio of 3.85, a current ratio of 3.87 and a debt-to-equity ratio of 0.76. ASP Isotopes Inc. has a 12-month low of $3.51 and a 12-month high of $14.49. The stock has a market cap of $594.84 million, a price-to-earnings ratio of -2.94 and a beta of 3.61. The stock’s fifty day simple moving average is $4.72 and its two-hundred day simple moving average is $5.26.
Insider Transactions at ASP Isotopes
In other news, CEO Paul Elliot Mann sold 83,759 shares of the business’s stock in a transaction on Wednesday, June 3rd. The shares were sold at an average price of $7.76, for a total value of $649,969.84. Following the sale, the chief executive officer owned 9,579,845 shares in the company, valued at approximately $74,339,597.20. The trade was a 0.87% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Heather Kiessling sold 23,124 shares of ASP Isotopes stock in a transaction dated Wednesday, July 1st. The stock was sold at an average price of $6.28, for a total transaction of $145,218.72. Following the sale, the chief financial officer directly owned 1,526,252 shares of the company’s stock, valued at $9,584,862.56. The trade was a 1.49% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 279,079 shares of company stock valued at $2,049,208 in the last three months. 14.40% of the stock is currently owned by company insiders.
Analyst Ratings Changes
Several analysts have weighed in on ASPI shares. Weiss Ratings reissued a “sell (d-)” rating on shares of ASP Isotopes in a research report on Wednesday, June 24th. Wall Street Zen upgraded ASP Isotopes from a “strong sell” rating to a “sell” rating in a research report on Saturday, August 22nd. Two equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $13.00.
Check Out Our Latest Analysis on ASPI
ASP Isotopes Profile
ASP Isotopes Inc, a development stage advanced materials company, focuses on the production, distribution, marketing, and sale of isotopes. It engages in the production and commercialization of Molybdenum-100, a non-radioactive isotope for the medical industry; Carbon-14; and Silicon-28. The company is also developing Quantum Enrichment technology to produce Ytterbium-176, Nickel-64, Lithium 6, Lithium7, and Uranium-235. ASP Isotopes Inc was incorporated in 2021 and is headquartered in Washington, District Of Columbia.
Featured Stories
- Five stocks we like better than ASP Isotopes
- 3 Financial Stocks Positioned for the Fed’s Next Move After Jackson Hole
- IREN’s AI Pivot Looks Real, But the Market Wanted a Faster Payoff After Earnings
- Boeing’s $131B F-15 Win: Mach 1 Momentum or Just Altitude?
- Okta Stock Surges 29%—Is $200 the Next Stop?
Receive News & Ratings for ASP Isotopes Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ASP Isotopes and related companies with MarketBeat.com's FREE daily email newsletter.
